PGFC
PVLA

Peapack-Gladstone Financial Corp’s Palvella Therapeutics PVLA Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$573K Buy
4,600
+1,600
+53% +$167K 0.01% 473
2025
Q4 		$314K Buy
+3,000
New +$256K ﹤0.01% 570

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Peapack-Gladstone Financial Corp's PVLA Position: Q1 2026 in Review

Peapack-Gladstone Financial Corp increased its Palvella Therapeutics (PVLA) stake by 53% in Q1 2026, buying an estimated $167K and bringing the position to 4,600 shares worth $573K. The position accounts for 0.01% of the portfolio, ranked #473.

Peapack-Gladstone Financial Corp first reported a position in PVLA in Q4 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Peapack-Gladstone Financial Corp held 4,600 shares of Palvella Therapeutics worth $573K as of Q1 2026.
  • Peapack-Gladstone Financial Corp bought 1,600 Palvella Therapeutics shares in Q1 2026, an estimated $167K.
  • Palvella Therapeutics made up 0.01% of Peapack-Gladstone Financial Corp's portfolio in Q1 2026, its #473 holding.
  • Peapack-Gladstone Financial Corp first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q1 2026, filed 15 May 2026.